Clinical Study Protocol Version (a)  H0P-MC-OA01  
 
Randomized, Placebo -Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of 
Osteoarthritis  
[STUDY_ID_REMOVED] 
Approval Date: 27- Mar- 2020 
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
1Title Page
Intervention -Specific Appendix (ISA) for LY3016859 :H0P -MC-OA01(a)
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the cli nical 
investigation of LY3016859 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries.  
Note to Regulatory Authorities:   This document may contain protected personal data and/or commercially confide ntial 
information exempt from public disclosure.  Eli Lilly and Company requests consultation regarding release/redaction prior to any 
public release.  In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be 
reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.
Master Protocol Title: A Master Protocol for Randomized, Placebo -Controlled, Phase 2 
Clinical Trials o f Multiple Intervent ions for the Treatment of Chronic 
Pain
Master Protocol Number: H0P-MC-CPMP
ISA Title : Rando mized, Placebo -Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for 
the Treatment of Osteoarthri tis
ISA Number: H0P-MC-OA01
Amendment Number: (a)
Compound :LY3016859
Study Phase: 2
Acronym: OA01
Sponsor Name: Eli Lilly  and Com pany
Legal Registered Address: Indianapo lis, Indiana USA 46285
Regulatory Agency Identifier Number(s)
Master Protocol IND: 144915 
Approval Date: Protocol Electronically Signed and Approved by Lilly ondate provi ded bel ow.
Approval Date: 27-Mar-2020 GMT
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Original Protocol 30 January 2020
Amendment (a)
Overall Rationale for the Amendment:
This amend ment address esFood and Drug Administration (FDA) feedback.
Section # and 
NameDescription of Change Brief Rationale
Section 1.3. 
Schedule of 
ActivitiesAddition of visit window for post -
randomization visitsAllows flexibility for participants
Section 1.3. 
Schedule of 
ActivitiesIncluded details forvital signs and 
targeted physical examination Per regulatory feedback
Section 1.3. 
Schedule of 
ActivitiesIncluded additional urine pregnancy 
sample collection and updated 
description of those who would be 
testedPer new toxicology data
Section 1.3. 
Schedule of 
ActivitiesIncluded additional sample collection 
time for hemoglobin A1cSample collection time missed in the original 
version
Section 2.3.1. 
Risk AssessmentRem oved language for women of 
childbearing potential and added 
language for fetal exposureWomen of childbearing potential are now allowed 
in the study; pregnant or breastfeeding women are 
not allowed
Section 4 Study 
DesignAmended post-treatme nt follow -up 
period instructionsUpdat ed to maximize data collection in the follow -
up period
Section 5.1. 
Inclusion CriteriaRem oved criterio nrelated to women 
not of childbearing potentialTo account for the addition of women of 
childbearing potential to the study per toxicology 
data
Section 5.1. 
Inclusion CriteriaRem oved criterio nrelated to 
supplements and vitaminsPotential to cause unintended screen failures and 
requirements sufficiently covered in the treatment 
period through lifestyle restrictio ns.
Section 5.2. 
Exclusion CriteriaAddition of language related to 
ophthalmologic diseasePer regulatory feedback
Section 5.2. 
Exclusion CriteriaAddition of criteri onrelated to women 
who are pregnant or breastfeedingPer regulatory feedback
Section 5.3. 
Lifesty le 
ConsiderationsRem oved language about local 
regulations for contraception use by 
men This language is intended for global studies.  This 
study will be conducted in the U nited States only.
Section 5.3. 
Lifesty le 
ConsiderationsRem oved language about supplements Per removal of related inclusion criterion
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
4Section # and 
NameDescription of Change Brief Rationale
Section 6.1.1. 
Special Treatment 
ConsiderationsAddition of special treatment 
considerationsPer regulatory feedback
Section 8.1.1. 
Physical 
ExaminationsNew section to i nclud edetails on 
targeted physical examination Per regulatory feedback
Section 10.2 , 
Appendix 2Addition of definitions and 
contraceptive guidance related to 
women of childbearing potentialTo account for the addition of women of 
childbearing potential to the study per toxicology 
data
Throughout the 
protocolMinor editorial and formatting changes Minor, therefore not described
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
5Table of Contents
1. Protocol Summary ...................................................................................................... 7
1.1. Synopsis ....................................................................................................................... 7
1.2. Schema ......................................................................................................................... 9
1.3. Schedule of Act ivities (SoA) ...................................................................................... 10
2. Introduction .............................................................................................................. 14
2.1. Study  Rati onale .......................................................................................................... 14
2.2. Backgro und................................................................................................................ 15
2.3. Benefit/Risk Assessment ............................................................................................ 16
2.3.1. Risk Assessment ......................................................................................................... 16
2.3.2. Benefit Assessment ..................................................................................................... 17
2.3.3. O verall Benefit: Risk Conclusio n................................................................................ 17
3. Objectives and Endpoints ......................................................................................... 18
4. Study Design ............................................................................................................. 19
4.1. Scientific Rationale for Study  Design ......................................................................... 20
4.2. Justification for Dose .................................................................................................. 20
4.3. End of Study  Definit ion.............................................................................................. 20
5. Study Population ...................................................................................................... 21
5.1. Inclusio n Cri teria........................................................................................................ 21
5.2. Exclusio n Cri teria....................................................................................................... 21
5.3. Lifest yle Considerat ions............................................................................................. 22
6. Study Intervention .................................................................................................... 23
6.1. Study  Intervent ion(s) Administered ............................................................................ 23
6.1.1. Speci al Treatm ent Consi derat ions............................................................................... 24
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 25
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 25
6.4. Study  Intervent ion Compliance ................................................................................... 25
6.5. Concomitant Therapy .................................................................................................25
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 26
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 26
8. Study Assessments and Procedures ......................................................................... 27
8.1. Safety Assessments .................................................................................................... 27
8.1.1. Physical Examinat ions................................................................................................ 27
8.1.2. Electrocardiograms ..................................................................................................... 27
8.1.3. Clinical Safety  Laboratory  Assessments ..................................................................... 27
8.2. Adverse Events and Serious Adverse Events .............................................................. 27
8.2.1. Infusio n Site Reacti ons ............................................................................................... 27
8.2.2. Hypersensi tivity Reacti ons and Infusio n-related Reacti ons ......................................... 27
8.2.3. Adverse Events of Special Interest .............................................................................. 28
8.3. Treat ment of Overdose ............................................................................................... 28
8.4. Pharmacokinet ics........................................................................................................ 28
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
68.5. Pharmacodynamics ..................................................................................................... 29
8.6. ................................................................................................................. 29
8.7. Immunogenicit y Assessments ..................................................................................... 29
9. Statistical Considerations ......................................................................................... 30
9.1. Statistical Hypotheses .................................................................................................30
9.2. Sample Si ze Determinat ion......................................................................................... 30
9.3. Popul ations for Analyses ............................................................................................ 30
9.4. Statistical Analyses ..................................................................................................... 30
9.4.1. General considerat ions................................................................................................ 31
9.4.2. Other Analyses ........................................................................................................... 31
9.5. Interim Analyses ......................................................................................................... 32
10. Suppor ting Documentation and Operational Considerations ................................ 33
10.1. Appendix 1: Clinical Laboratory  Tests ........................................................................ 33
10.2. Appendix 2: Definit ions of Reproductive Requirements and 
Contraception Guidance ............................................................................................. 34
10.3. Appendix 3: Reco mmended Laboratory Test ing for 
Hypersensi tivity Events and Infusio n-related Reacti ons.............................................. 37
11. References ................................................................................................................. 38
CCI
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
71. Protocol Summary
1.1. Synopsis
Protocol Title:
Randomized, placebo -controlled, Phase 2 clinical trial to evaluate LY3016859 for the treatment 
of osteoarthri tis
Rationale :
The purpose of this study  is to test whether LY3016859 is efficacious in relieving knee pain due 
to osteoarthrit is (OA).  LY3016859 is a high affinity  humanized immunoglobulin G (IgG)4
monoclonal antibody  that binds to key  residues in the C -terminal regions of transforming growth 
factor -α(TGF -α) and epiregulin, prevent ing their binding to the e pidermal growth factor receptor
(EGFR).  
Data will be collected to assess the safet y, and tol erabili ty of LY3016859 in this study  popul ation. 
Pharmacokinet ic (PK)properti es, pharmacodynamic (PD) effects and immunogenicit y profile 
will also be explored .  
The totalit y of data fro m this proof -of-concept study will assess the
benefit s and risksassociated with LY3016859 and inform  decisio ns for the clinical development 
of LY3016859.
Objectives and Endpoint s
The primary  and secondary  object ives and endpo ints are stated in the master protocol H0P -MC-
CPMP (CPMP) and OA disease -state addendum  (DSA; H0P -MC-CPMP[ 1]).
Overall Design
This is a 26-week, Phase 2 ,randomized, double -blind, pl acebo -controlled study that will 
compare LY3016859 versus placebo in participants with OAin the knee .
Disclosure Statement : This is a rando mized, investigator -and participant -blind, placebo -
controlled, Phase 2 clinical trial . 
Number of Participant s:
Approximately  125 participants will be rando mly assigned to study  interventi on(84 LY3016859 
and 41 placebo) with the assumption that 15% of the participants will drop out prior to the end of 
the double -blind treatment period.
Intervention Groups and Duration :
This 26 -week study  includes an 8- week double -blind treatment period and an 18 -week follow-up 
period.
Parti cipants will receive an intravenous (IV) infusion every 2 weeks for a total of 4 infusio ns.
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
8Intervention Name LY3016859 Placebo
Dosage Level(s) 750 mg starting dose
500 mg subsequent dosesNot applicable
Route of Administration
and duration1 hour IV infusion 1 hour IV infusion
Parti cipants will be m onitored f or at l east 4 hours after complet ion of each infusio n.
Data Monitoring Committee: Yes
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
91.2. Schema
*Medication washout and preliminary data entry period begins .
** Randomization to either LY3016859 or placebo.  
ǂEach participant receives a 1 hour infusion at Visits 3, 4, 5, and 6.
Abbreviations:  IV = intravenous; PDEP =preliminary data entry period; V =visit.
Washout
& PDEPUp to -6 
months
V1 V3**Week 2
V4Week 4
V5Week 6
V6Week 8
V7-10 days to V3
V2*
Screening
PeriodRandomization 
Double -Blind
Period
Placebo IV infusionǂLY3016859 IV infusionǂWeek 26
V803
Follow-upWeek 12
V801Week 16
V802
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
101.3. Schedule of Activities (SoA)
This SoA shows visits and procedures unique to the intervent ion-specific appendix ( ISA)H0P-MC-OA01 ( OA01 )for LY3016859.  
Please refer to master protocol H0P-MC-CPMP (CPMP )and the osteoarthrit is (OA) disease -state addendum ( DSA )H0P-MC-
CPMP(1) SoAs for addit ional information.   
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
11H0P-MC-OA01
ISARandomization Double -Blind Treatment Follow -up Early
DiscontinuationNotes
Visit Number V3 V4 V5 V6 V7 V801 V802 V803 ED
Study Week 0 2 4 6 8 12 16 26
Visit Window 
(days)±3 ±3 ±3 ±3 ±5 ±7 ±7 Minimal interval between 2 doses cannot be shorter 
than 11 days.
Physical 
examinationX X X X X X X X X Targeted exam for skin, eyes, mouth, lungs and GI 
tract should be performed at each visit, in addition to 
any symptom driven exam.  Full physical exam 
should be performed at Visit 803 or ED.
Weight X
Vital signs X X X X X X X X Includes respiratory rate, blood pressure, 
temperature and pulse rate.  All vital signs are 
collected before study intervention infusion on V3 -6.
ECG X X X Single safety ECGs
Study  
intervention IV 
infusionX X X X 1 hour IV administration
The timing between randomization and the first IV 
infusion may be up to, but not longer than 2 business 
days to reduce pa rticipan t burden.
Adverse events X X X
Concomitant 
medicationX X X
Rescue 
medication 
usage reportingX If the participant discontinues after V801, this 
assessment is not needed for ED per the CPMP SoA .
NRS X If the participant discontinues after V801, this 
assessment is not needed for ED per the CPMP SoA.
PGI X If the participant discontinues after V801, this 
assessment is not needed for ED per the CPMP SoA.
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
12H0P-MC-OA01
ISARandomization Double -Blind Treatment Follow -up Early
DiscontinuationNotes
Visit Number V3 V4 V5 V6 V7 V801 V802 V803 ED
Study Week 0 2 4 6 8 12 16 26
Visit Window 
(days)±3 ±3 ±3 ±3 ±5 ±7 ±7 Minimal interval between 2 doses cannot be shorter 
than 11 days.
WOMAC X If the participant discontinues after V801, this 
assessment is not needed for ED per the CPMP SoA .
C-SSRS X X Use C-SSRS Since Last Visit version.  
Self-Harm 
Supplement 
FormX X
Self-Harm 
Follow -up FormX X Required if triggered by the Self -Harm Supplement 
Form per instructions.
Hematology X X X
Chemistry X X X X X
Urine 
ChemistriesX X X X X XXX
Urinalysis X
Urine pregnancy X X X X X X X For all premenopausal females or postmenopausal 
female s<50 years of age
V3: collect sample before dosing
Urine drug 
screenX X X
Hemogl obin 
A1cX X X X
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
13H0P-MC-OA01
ISARandomization Double -Blind Treatment Follow -up Early
DiscontinuationNotes
Visit Number V3 V4 V5 V6 V7 V801 V802 V803 ED
Study Week 0 2 4 6 8 12 16 26
Visit Window 
(days)±3 ±3 ±3 ±3 ±5 ±7 ±7 Minimal interval between 2 doses cannot be shorter 
than 11 days.
PK sample X X X X X X X X X V3-V6:  collect samples before IV infusion starts 
and within 15 minutes after IV infusion is complete.
V7 –V803: single sample collected at any time.
Obtain PK samples from opposite arm used for IV 
infusion.  
Record date and time of collection.
Immunogenicity 
(ADA) sampleX X X X X X X V3-6:  collect sample before IV infusion starts
Epiregulin 
sampleX X X X X X X X V3-6:  collect sample before IV infusion starts.
V7-V803: single sample collected at any time to 
match PK.
Abbreviations:  ADA = anti -drug antibody; C-SSRS = Columbia Suicide Severity Rating Scale; ECG = electrocardiogram; GI = gastrointestinal; IV= intravenous; NRS = 
Numeric Rating Scale for pain ; PGI = Patient Global Impression of change; PK = pharmacokinetic; V = visit ; WOMAC = Western Ontario and McMaster University Arthritis 
Index .
CCI
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
142. Introduction
This ISA OA01 is an appendix to the master protocol CPMP and contains unique study  elements 
specific for LY3016859 . The m aster protocol  contains the overarching study  elements that 
govern the OA DSA CPMP(1) and this ISA OA01.  
LY3016859 is a high affinit y humanized immunoglo bulin G (IgG)4 monocl onal ant ibody  that 
binds to key  residues in the C -terminal regio ns of transforming growth factor -α(TGF -α) and 
epiregulin, preventing their binding to the e pidermal growth factor receptor (EGFR).  
Engagement of LY3016859 results in internalizat ion of the membrane -spanning ligands and 
neutralizat ion of mature ligand activit y in vitro .  
The EGFR and epiregulin are associ ated wi th pain processing (Martin et al. 2017).  Epiregulin is 
increased in blood after nerve injury/insult (Martin et al. 2017).  Inhibit ion of EGFR with 
clinically available compound s strongly reduces nocifensive behavior in mouse models of 
inflammatory  and chronic pain, including spinal nerve injury  and chronic constriction injury
(Martin et al. 2017) .
TGF -α has also been implicated in so me chronic pain condit ions, especially  with pain in OA.  
For instance, a single nucleotide polymorphism (SNP) of TGF -α has been associated with 
increased risk of developing OA of the knee (Cui et al .2017), and in 1reported case study  
(Moryl et al .2006) a l ung cancer patient receiving treatm ent wi th the EGFR ty rosine kinase 
inhibitor gefit inib reported a marked improvement in her OAsymptom s.  The reported pain 
relief persisted while on treatment ,but painful symptoms returned when treatment was 
discontinued due to intolerance ofEGFR inhibitor associated side effects .
Non-controlled reports show that EGFR inhibit ion 
by various oncol ogic drugs provi des rapi d 
relief o f pain ( Kersten et at. 2013; Kersten et al. 2015; Juhasz et al. 2013); and the pain relief was 
independent of diseas e progressi on (Kersten and Cam eron 2012).  
2.1. Study Rationale
The purpose of this study  is to test whether LY3016859 is efficacious in relieving knee pain due 
toOA.  Data will be collected to assess the safet y and tol erabilit y of LY3016859 in this study  
population. Pharmacokinet ic (PK)properti es, pharmacodynamic (PD) effects and 
immunogenicit y profile will  also be expl ored.  The totalit y of data fro m this proof -of concept 
study will assess the benefit s and risksassociated wi thLY3016859 and inform  decisio nsfor the 
clinical development of LY3016859 .
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
152.2. Background
LY3016859 was initially devel oped f or the treatment of diabeticnephropathy (DN) and 2 
clinical studies were completed.
Study I5V-MC -TGAA (TGAA)
Population Healthy  participants
Study Desi gn Placebo -controlled, randomized, single -dose escalation
LY30168 59 
DoseIntravenous (IV) infusion and subcutaneous:  0.1, 1, 10, 50, 250, and 750 mg
Objective sEvaluate safety, tolerability, and pharmacokinetics after single IV and subcutaneous 
dosing.
Study I5V-MC -TGAB (TGAB)
Population Participants with diabetic nephropathy 
Study Design 2-part, placebo - controlled, randomized, multiple dose escalation and parallel dose study
LY30168 59 
DosePart A: dose range of 10 to 750 mg ,administered as a 60 -minute IV infusion once ever y 
3weeks for a total of 2 doses
Part B: 60-minute IV infusion once ever y 3weeks up to 5 doses, if tolerated
Doses did not exceed the maximum tolerated dose from Part A .
Objectives Evaluate safety, tolerability ,and pharmacokinetics and pharmacodynamics.
Change f rom baseline in proteinuria at 16 weeks.
Pharmacokinetics 
LY3016859 serum concentration increased more than proportionally  with dose; and the terminal 
half-life increased wit h dose (approaching 18 days at higher doses) , consistent with target -
mediated drug disposit ion.  
Pharmacodynamics
LY3016859 demonstrated dose -related target engagement for both TGF -α and epiregulin .
Safety
Intravenous doses of up to 750 m g LY3016859 were safe a nd reasonably  well tolerated.
Adetailed description o f the chemistry , pharmaco logy, efficacy , and safet y of LY3016859 is 
provi ded in the Invest igator’s Brochure (IB).
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
162.3. Benefit/Risk Assessment
The IBprovides d etailed informat ion about the known and expecte d benefit s and risks and 
reasonably  expected adverse events (AEs) of LY3016859.
2.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Study Intervention LY3016859
Development of treatment -emergent 
anti-drug antibodies (TE ADA) .Incidence of TE ADA was 50% after 
a single dose, and up to 57% after 
multiple doses.Collect samples up to 20 weeks after 
last dose to characterize ADA 
profile .
IVinfusion may be associated with 
infusion reactions and 
hypersensitivity reactions . LY3016859 is a monoclonal 
antibody that will be administered 
via IV infusion. Hypersensitivity 
reactions and infusion reactions may 
occur during treatment with such 
agents .Monitor infusion reactions and 
hypersensitivity reactions .
Guidance on management of 
infusion andhypersensitivity 
reactions are in Sections 8.2.1 . and 
8.2.2.
Dermatological adverse reactions 
similar to EGFR antagonistsOne healthy  participant who 
received a single dose of 1 mg 
LY3016859 experienced a rash that 
was considered similar to those 
associated with EGFR antagonists .Collect dermatological AEs .
Stop dosing for severe 
dermatological AEs .
Changes in eGFR in pa rticipa nts 
with diabetic nephropathy (DN)A modest and non -statis ti
cally
significant decrease in eGFR was 
observed in pa rticipa nts with DN 
who receive dLY3016859 in Part B 
of Study TGAB, but not in healthy 
participants in Study TGAA .Exclude pa rticipants with mod erate 
or severe renal impairment in the 
study.
Short dosing duration .
Monitor eGFR and stop dosing if 
necessary .
 
Fetal harm due to in utero exposure No effects on embryo -fetal 
development in enhanced pilot 
embryo -fetal development studies in 
rats and rabbits .  Definitive 
developmental and reproductive 
toxicity studies are not yet 
completed.Do not enroll women who are 
pregnant or breastfeeding in studies 
forLY3016859 .
Study Procedures
Participa nt may  experience 
increased OA symptoms.Medications that relieve OA pain 
will not be allowed until Visit 801 .Rescue medication is permitted .
Standard treatment of OA may be 
restarted after Visit 801 based on 
investigator discretion .
Abbreviations:  ADA = anti -drug antibodies; AE = adverse events; DN = diabetic nephropathy; EGFR = epidermal 
growth factor receptor; eGFR = estimated glomerular filtration rate; IV = intravenous; OA = osteoarthritis; TE = 
treatment emergent; TGAA = study I5V-MC -TGAA; TGAB = study I5V -MC -TGAB.
CCI
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
172.3.2. Benefit Assessment
Potenti al benefi tsfor the study  participants include 
study -related medical procedures 
ophysical examinat ions, 
olaboratory  tests 
oelectrocardi ogram s (ECGs)
detailed evaluat ions of OA 
oknee examinat ions
oknee X -rays, and
OA associ ated questi onnaires that 
may improve pa rticipants understanding their own 
condi tion. 
As part of Study  CPMP, parti cipants to thi s ISA will  report thei r experi ence using standard tools
that will contribute to the ass essment of novel treatment sfor OA. In addition, data collected 
from this study  may also improve our understanding of OA pathogenesis . Both of which may  
lead to the development of a new treatm ent wi th improved safet y and efficacy  profile com pared 
to stan dard of care .
2.3.3. Overall Benefit: Risk Conclusion
The measures taken to minimize risk to participants in this study andthe potenti al risks i dentified 
in associat ion with ISAOA01 are justified by the ant icipated benefits to participants with OA.
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
183. Objectives and Endpoints
The master protocol  CPMP and OA DSA CPMP (1)include objectives and endpo ints applicable 
for this study . This table describes object ives and endpo ints specific for LY3016859.
Objectives Endpoints
Tertiary/Exploratory
Characterize the pharmacokinetics and 
pharmacodynamics of LY3016859 after multiple 
intravenous infusions in participants with osteoarthritisAssessment of serum concentrations of LY3016859 
and epiregulin to enable pharmacokinetic and 
pharmacodynamic evaluation s
Characterize immunogenicity of LY3016859 Appearance of anti -drug antibodies and neutralizing 
antibodies to LY3016859
Explo re the effect of LY3016859 on the kidney Assessment of 
urine albumin/creatinine ratio
urine protein/creatinine ratio
eGFR
Abbreviations:  eGFR = estimated glomerular filtration rate.
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
194. Study Design
Master p rotocol CPMP describes the overall study  design and study  design rati onale.   This 
section describes visits and overall procedures unique to ISA OA01 for LY3016859 in addit ion
to the procedures outlined in CPMP and CPMP(1) .
Double -blind Treatment Period (Visits 3 through 7)
Each visit is an outpatient visit.
At Visit 3
participants are randomized to LY3016859 or placebo  
the site com pletes the OA01 baseline procedures and sample co llection 
participants receive their first dose of study  intervent ionvia IV infusio n over 1 hour 
the site observes part icipants in the clinic for at least 4 hours after the completion o f the 
IV infusio n 
the site com plete s all post -treatm ent sam ple collectio n and safety  monitoring , and
the site instructs participants to continue with study  restri ctions and Numeric Rat ing 
Scale (NRS )diary entri es before thei r visit discharge .
At Visits 4 through 6
the site revi ews available safet y data and com pletes pre -dose procedures and sample 
collect ion
participants receive an IV infusio n over 1 hour 
the site observes part icipants in the clinic for at least 4 hours after the completion o f the 
IV infusio n
the site com pletes all post- treatm ent sam ple collectio n and safety  monitoring , and
the site instructs participants to continue with study  restri ctions and NRS diary  entries 
before their visit discharge .
At Visit 7
the site com pletes all procedures and sample co llection noted in the SoA s
no intervent ion is administered at this visit , and
the site instructs participants to continue with study  restri ctions and NRS diary  entries 
before their visit discharge .
Post-treatment Follow -up Period (Visits 801- 803) 
Parti cipants m ust com plete 3 post -treatm ent follow-up vi sits for safet y, PK and immunogenicit y 
assessment at Visits 801 -803, according to the SoA.
The site schedules Visit 801 approximately 4 weeks after Visit 7. 
At Visit 801, participants return the device for NRS diary co llection. 
At Visit 803, the participants are discharged from the study . 
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
20If the participant receives at least one dose of intervent ion and discontinues during the double-
blind treatment period, they  shoul d com plete early discontinuat ionproce dures per the CPMP 
Protocol  SoA and Visit 801 shoul d be scheduled approximately  30 days after the l ast dose of 
study  interventi on.
4.1. Scientific Rationale for Study Design
The m aster protocol  describes the overall study  design rati onale.
Efficacy data will be co llected up to 6weeks after the last dose, based on the long PK half -life 
and potenti al sustained target engagement of LY30 16859.
Safety, PK, PD and immunogen icitysamples will be collected up to 20 weeks after the l ast 
administrati on of  intervent ion to characterize the safety and clinical immunogenicit yprofile.
4.2. Justification for Dose
The proposed dose for proof -of-concept i s a 750 -mg starting dose fo llowed by 500 mg every  
2weeks IV for a total of 4 doses.  The dose level and durati on are based on the available 
toxicology, safet y, PK and PD data fro m the com pleted studi esdetailed in the LY3016859 IB. 
Briefly, the proposed dose regimen maintains an approximate 10
-fold margin o f safety  (MOS) 
relative to the no-observed -adverse -effect l evel (NOAEL) for both rat and monkey  repeated dose 
toxicology studi es (Table 4.5 in the IB) and is expected to achieve steady state exposure similar 
to the 750 mg every 3 weeks dosing regimen tested in Study  TGAB.  The safet y data fro m the 
complete d TGAA and TGAB studi es, and the clinical management plan support testing the 
proposed dose regimen in pa rticipants with various chroni c pain condi tions. 
The PK analyses show asimilar PK profile for LY3016859 in healt hy participan ts and pat ients 
with various degrees of renal impairment, which is expected for a monoclonal ant ibody .  
While the degree of target- engagement required for analgesic efficacy for LY3016859 has not 
been established in the clinic , the proposed dosing regimen is expected to reach steady -state 
within a m onth  
.  If the epiregulin blockade is beneficial for OA pain condit ions, then this l evel of target 
engagement i s expected to enable analgesic efficacy .
4.3. End of Study Definition
A participant is considered to have co mpleted th isISA if heor she has completed all required 
phases of the study  including the last scheduled procedure shown in the ISA Schedule o f 
Activities.
The end o f the study  is defined as the date of the last vi sit of the l ast parti cipant in the study  or 
last scheduled procedure shown in the ISA Schedule of Act ivities for the l ast parti cipant.
CCI
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
215. Study Population
The m aster p rotocol CPMP and OA DSA CPMP (1) provide eligibilit y criteria that m ust be 
followed for thisstudy .  LY3016859 specific inclusion and exclusio n criteria are listed here.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all the fo llowing c riteria apply:
[1000] are men or women who abide by the reproductive and contraceptive requi rements 
provi ded in OA01 Section 10.2, Appendix 2
[1001] arewilling to discontinue all pain medicat ions for condit ion under study  except 
rescue m edicati on permitted unt il V801 in the fo llow-up period
[1002] must have venous access in both arms for IV infusion and sample collection .
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
[1003] have had an intra-articular injection o f hyaluronic acid wit hin 24 weeks o f Visit 2
[1004] h ave an eGFR of less than 70 ml/min/1.73m 2 based on CKD -EPI formula at Vi sit 1 
or Visit 2
[1005] Have any clinically  serious or unstable cardi ovascul ar, musculo skeletal  disorder, 
gastrointestinal, endocrino logic, hematol ogic, hepati c, metabo lic, urologic, 
pulmo nary, derm atologic, immunol ogic, or ophthalmo logicdisease within 3 m onths 
of Visi t 3
Prior/Concomitant Therapy
[1006] have received any  antibodi es against nerve growth factor (NGF) , or antibodies 
against EGFR, or EGFR tyrosine kinase inhibitors
[1007] have a h istory  of allergic reactions to monoclonal antibodies, or clinically 
significant m ultiple or severe drug allergies, including but not limited to ery thema 
multiforme major, linear immunogl obulin A dermatosis, toxic epidermal necro lysis, 
or exfo liative dermat it
is
[1008] have a history  or presence of uncontrolled asthma, eczema, significant atopy , 
significant heredi tary angi oedema or comm on variable immune deficiency , and
Reproductive
[1009] are wom en who are pregnant or breastfeeding .
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
225.3. Lifestyle Considerations
Reproductive and Contraception Requiremen ts
Reproductive requirements and c ontraceptive guidance areprovided in OA01 Appendix 2, 
Secti on 10.2.  
Caffeine and Alcohol
Parti cipants shoul d maintain thei r usual  caffeine intake.  
Parti cipants shoul d limi t thei r alcohol  consumpti on for the durati on of  the study .  
Men up to the age of 65 should not exceed an average weekly alcoho l intake of21 units per 
week .  
Men over the age of 65 and women should not exceed an average weekly alco hol intake of
14units per week.
One unit of alcoho l equals
12 oz or 360 mL of beer 
5 oz or 150 mL of wine, or
1.5 oz or 45 mL of distilled spirits .
Activities
Parti cipants are requi red to main tain similar l evels of activit y during the doubl e-blind study  
period. Starting a new exercise program or new strenuous activit y is not allowed. 
Parti cipants who receive physical therapy  for OA of  the index knee should remain on the same 
therapy program  (intensit y and frequency) from Visit 3 to Visit 801.   New programs may be 
initiated after Visit 801.
Exposure to Sun
Parti cipants shoul d use sun protection and avoid sunbathing and use of sun beds for the duration 
of the study .  Sun protecti on m ayconsist of protective clothing or SPF 50 lotion.
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
236. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to a study  parti cipant according to the 
study  protocol .
6.1. Study Intervention(s) Administered
The study  intervent ion will be administered via a slow IV infusio n over approximately 1 hour by  
blinded site personnel.  The infusio n rate may be reduced as deemed necessary  if an infusi on 
reacti on is observed.  Participants will be mo nitored for at least 4 hours after complet ion of each
infusio n. Site must have resuscitation equipment, emergency drugs and appropriately training 
staff avai lable during the infusio n and for at least 4 hours after the complet ion of the infusio n. 
Parti cipants shoul d not use tobacco products from 1 hour before thestart of dosing unt il after 
collect ion of the final PK or PDsampleafter dosing .  
Intervention 
NameLY3016859 Placebo
Type Biologic Not applicable
Dose 
FormulationLyophilized powder reconstituted with sterile water 0.9% Sodium chloride solution
Unit Dose 
Strength(s)75 mg/vial Not applicable
Dosage Level(s) 750 mg starting dose
500 mg subsequent dosesNot applicable
Route of 
Administration1 hour IV infusion 1 hour IV infusion
Use experimental placebo
IMP and NIMP IMP and NIMP IMP and NIMP
Sourcing LY3016859 from Lilly
If needed, saline for reconstitution of IMP will be site 
sourced.Placebo will be procured, packaged, 
labeled, distributed and dispensed as 
IMP by Lilly
Packaging and 
LabelingThe ly ophilized powder and sterile diluent for 
infusionwill be provided in separate glass vial s. Each 
vialwill be labeled as required per country 
requirementPlacebo will be provided in a glass 
vial. Each vialwill be labeled as 
required per country requirement
Abbreviations:  IMP = investigational medicinal product; NIMP = non -investigational medicinal product.
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
246.1.1. Special Treatment Considerations
6.1.1.1. Premedication for Infusions
Prem edicat ion for infusio ns is not pl anned.  However, if an infusion react ion occurs, the study  
investigator(s ) should determine the appropri ate premedication for subsequent infusio ns for that 
participant .
The invest igator sand sponsor may decide to usepremedicat ion for all participants.  They  will 
decide this if the frequency of infusio n reactions amo ng participants warrants it .
Any premedicat ions given will be documented as a concomitant therapy  (see Secti on6.5).
6.1.1.2. Management of Infusion Reactions
All participants shoul d be m onitored cl osely , asthere is a risk of infusio n reaction and 
hypersensit ivity (incl uding anaphylaxis) with any bi ological  agent.  
Symptoms and Signs
Symptom s and si gns that m ay occur as part of an infusio n reaction include, but are not limited to 
fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash, 
pruri tus, myalgia, and dizziness.  
Site Needs
The clinical site shoul d have necessary  equipment and medicat ions for the m anagement of any 
infusio n reaction, which may include but is not limited to oxy gen, IV fluid, epinephrine, 
acetaminophen and ant ihistamine.
Management of Infusion Reaction s
Invest igators should grade the severit y of the infusio n reaction andmanage infusio n react ions 
based on standard of care and their clinical  judgment .  If an infusio n reaction occurs, then 
supportive care should be used in accordance with the signs and symptoms.
This table outl ines guidance when a mild to moderate infusio n reaction occurs.
If… Then…
a mild to moderate infusion reaction occurs the infusion rate should be slowed or stopped depending 
on the symptoms or signs present.
For example, reducing the rate by 50% from 
2 mL/minute to 1 mL/ minute .
the infusion rate is slowed the infusion should be completed at the slower rate, 
as tolerated.
subsequent infusions may be administered at the 
discretio n of the investigator in agreement with the 
Lilly  medical monitor. 
the inf usion rate is slowed, and subsequent infusions are 
continuedthe infusion rate must be maintained at the slowest 
tolerated rate used. 
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
25The s tudy intervent ion infusio n shoul d be stopped immediately  and perm anent ly if it isan 
infusio n reaction
with systemic invo lvement, including, but not limited to significant treatment emergent 
hypotension, bronchospasm, or wide -spread urti caria 
that does not respond to a slower infusion rate or oral medications
that is determined as clinically  significant by the investi gator.  
If a participant permanent ly discontinues from  study  intervent ion, they  shoul dcomplete AE
monitoring and other procedures as stated in Section 4, Study  Design, and the CPMP and OA01 
SoAs.
6.2. Preparation/Handling/Storage/Accountability
Study  intervent ion and placebo require refrigerat ion.
Study  intervent ion and placebo will be prepared an d verified by unblinded site 
personnel.
6.3. Measures to Minimize Bias: Randomization and Blinding
No addi tional stratificat ion factors are considered for this ISA.  
6.4. Study Intervention Compliance
Participants will receive study  intervent ion directly fro m the invest igator or designee, under 
medical supervisio n.  The date and time of each study  intervent ionadministered in the clinic will 
be recorded in the source documents and case report form ( CRF ).  Ad ministration of intervent ion
and study  parti cipant i dentification will  be confirmed at the time of dosing by a member of the 
study  site staff other than the person administering the study  interventi on.  
6.5. Concomitant Therapy
All conco mitant therapi es that are part of routine care for other comorbidit ies besides OA, are 
allowed and can be used during the study , ifit is permitted based on the inclusio n and exclusio n 
criteria.   
A list of medications that are prohibited from Visit 2 to Visi t 801 for parti cipants randomized to 
this ISA study  will be provi ded.  Participants may return to thei r standard -of-care after Visit 801 
is co mpleted, as clinically appropriate.
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
267. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Protocol  CPMP provides the reasons and procedures for discont inuat ionof interventi on and 
participant discont inuat ion that must be followed for this study .  LY3016859 specific 
inform ation is included here.
7.1. Discontinuation of Study Intervention
If the invest igator, after consultation with the sponsor -designated medical mo nitor, determines 
that a sy stemic hypersensit ivity reacti on or a seri ous infusi on reacti on has occurred related to 
study  interventi onadministrati on, the parti cipant shoul d be perm anent ly discont inued fro m the 
study  interventi on.
A participant should be discont inued fro m study  intervent ion if they experience aderm atological 
adverse reaction, such as acn eiform  rash, that isrelated to study  intervent ion, and is either mild 
to moderate anddoesnot respond to topical treatment oris severe .The participan t may cont inue 
in the study  at the di scret ion of the invest igator in consultation wit h the medical m onitor or study  
sponsor phy sician/scient ist.
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
278. Study Assessments and Procedures
Study  procedures and their timing are summarized in the protocol CPMP , OA DSA CPMP(1), 
and ISA OA01 SoAs.
LY3016859 specific assessments and procedures are describ ed here.
8.1. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA.
8.1.1. Phys ical Examinations
Targeted physical examinat ions of skin, eyes, month, lungs and GI tract will be performed at 
each visit as described in the SoA.Any clinically significant abnormal physical examinat ion 
findings will be reported as AEs. 
8.1.2. Electrocardiograms
Single 12-lead ECG will be obtained as outlined in the SoA using an ECG machine that 
autom atically calculates the heart rate and measures pulse rate , QRS, QT , and QTc .
8.1.3.
Clinical Safety Laboratory Assessments
See OA01 Appendix 1 (Secti on 10.1)for the list of clinical laboratory  tests to be performed and 
to the So A for the timing and frequency for ISA OA01 .
8.2. Adverse Events and Serious Adverse Events
8.2.1. Infusion Site Reactions
Symptom s of a l ocal infusi on site reacti on may  include ery thema, indurat ion, pain, pruritus, and 
edem a.If an infusio n site event is reported, the AE will be recorded, and additional data will be 
provi ded to the sponsor in the CRF.
Addit ional blood and urine samples should be co llected as described in OA01 Secti on 10.3, 
Appendix 3, “Recommended Laboratory  Test ing for Hy persensi tivity Events”.   Laboratory 
resul ts are provi ded to the sponsor vi a the central  laboratory .
8.2.2. Hypersensitivity Reactions and Infusion -related Reactions
Many  drugs, but parti cularly biologic agents ,carry the ri sk of systemic hypersensit ivity 
reacti ons. Drugs administered via IV infusio n may lead to a sy stemic infusio n-related reacti on. 
If such a react ion occurs, a dditional data describi ng each symptom  shoul d be provi dedto the 
sponsor in the CRF.  
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  parti cipants are receiving study  intervent ion. It is recommended that 
participants who experience a systemic reaction be treated per the local standard of care .  
In the case of generalized urticaria oranaphylaxis ,or moderate to severe infusio n-related 
reacti ons, additional bl ood and urine samples should be collected as described in OA01 
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
28Secti on 10.3, Appendix 3, “ Reco mmended Laboratory  Testing for Hy persensi tivity Events”.   
Laboratory  resul ts are provi ded to the sponsor via the c entral  laboratory .
8.2.3. Adverse Events of Special Interest
Dermatological adverse reactions
EGFR ant ibodies or EGFR -associ ated ty rosine kinase inhibitors are associated with various 
derm atological AEs, including acn eiform  rashes, xerosis, pruri tis, and photosensit ivity. 
Secondary  infect ion can also develop. 
Parti cipants shoul d usesun protecti onduring the study  period. Dermatological adverse reaction s
shoul d be managed by the invest igator according to standard of care. Discont inuat ion of 
treatm ent m ay be considered if theseAEs do not respond to topical treatment or are widespread
(>30% body  surface area) or are severe.
If any o f these AEs are reported, sites will be prompted to provide additional informat ion. 
Renal Function
Changes in eGFR were observed in pa rticipan ts with di abetic nephropathy  in Study TGAB
(Secti on2.2). Such changes were reversible and were not associ ated wi th increase in proteinuria .  
Blood and urine samples will be collected to characterize the effects of LY3016859 on renal 
funct ionand eGFR will be mo nitored during the study .
8.3. Treatment of Overdose
In case of suspected overdose, participants should be mo nitored for any  signs or symptom s of 
adverse reactions or effects, and supportive care should be provided as necessary. 
8.4. Pharmacokinetic s
Venous blood samples of approximately 4 mL will be collected for measurement of LY3016859
concentrations as specified in the SoA .Samples will be used to evaluate the PK of LY3016859 .  
A maximum of 3samples m ay be collected at additional t ime po ints during the study  if 
warranted and agreed upon between the invest igator and the sponsor.
Instructi ons for the collect ion and handling of bio logical samples will be provided by Lilly . 
Site personnel will record
The date and time (24-hour clock time) of LY3016859 administration (start andend of 
infusio n), and
The date and time (24 -hour clock time) of each PK sample.
It is essent ial that the times are recorded accurately.
Pharmacokinet icsamples will be re tained for a m aximum  of 2 years fo llowing last subject visit 
for the study .
 
CCI
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
298.5. Pharmacodynamics
Venous blood samples of approximately 4 mL each will be co llected for the measurement of 
epiregulin as specified in the SoA .Any remaining blood samples may be used to test other 
potenti al PD endpoints, including, but not limited to TGF -α.
Instructi ons for the collect ion and handling of bio logical samples will be provided by Lilly.
8.7. Immunogenicity Assessments
Visits and times
At the visit s and t imes specified in the SoA,predose venous bl ood sam ples will  be collected to 
determine antibody  producti on against LY3016859 .  The actual date and time (24-hour clock 
time) of each sample collection will be recorded.
If the immunogenicit y sample at the last scheduled assessment or discont inuat ion visit is 
treatm ent-emergent (TE) anti -drug antibody  (ADA) posit ive(as defined in Secti on 9.4.2.1 ), 
additional samples may be taken unt il the signal returns to baseline (i.e. ,no longer TE -ADA 
positive) or for up to 1 y ear after l ast dose.
To ai d interpretat ion of these results, a predose blood sample for PK analysis will be collected at 
the sam e time points .
Sample collection, handling, and use
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor.
Immunogenicit y will be assessed by  a validated assay  designed to detect ADAs in the presence 
of LY3016859 at a laboratory approved by  the sponsor.  Antibodies may be further characterized 
for their abili ty to neutralize the activit y of LY3016859.   
Sample retention
Sample retenti onis described in protocol  CPMP, Appendix 1, Section 10.1.12 .
CCI
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
309. Statistical Considerations
The m aster protocol  and OA DSA provide statist ical considerat ions.  LY3016859 specific 
considerations are described here. 
9.1. Statistical Hypotheses
The m aster protocol  CPMP describes the primary  hypothesis.
 
 
The key  secondary  null hypothesis is that there is no difference between LY3016859 and pl acebo 
on the key secondary endpo int, the mean change from baseline to endpoint for the WOMAC® 
Pain Subscale Score.  
 
9.2. Sample Size Determination
Approximately  125 pa rticipantswill be rando mized in a 2:1 rati o toLY3016859 and placebo , 
respectively .It is expected that approximately 107
participant swill co mpletethe doubl e-blind 
treatm ent peri od of  the study . 
 
 
 If the re is
no treatment difference between placebo and LY3016859 , the probabilit y of passing the efficacy  
criterion specified above (i .e., falsepositive) i s approximately  0.1. The simulat ion for the power 
calculat ion and sample size determinati on was carried out in FACTS Version 6.0.
9.3. Populations for Analyses
The populat ions are defined in protocol CPMP.
The pharmacokinet ic popu lation includes all randomized participants who received a full dose of 
LY3016859 at Visit 3 and have at least 1 evaluable PK sample co llected prior to dosing at or 
after Visi t 4. 
9.4. Statistical Analyses
Any change to the data analysis methods described in t his ISA will require an amendment only if 
it changes a principal feature of the ISA.  Any  other change to the data analysis methods 
described, and the just ificat ion for making the change, will be described in the statistical analysis 
plan (SAP)and the clinical study  report.  Addi tional expl oratory  analyses of the data will be 
conducted as deemed appropriate.
CCI
CCI
CCI
CCI
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
31The ISA SAP will be finalized prior to unblinding, and it will include a more technical and 
detailed descript ion of the statist ical analyses descri bed in this section. 
9.4.1. General considerations
The primary  endpoint and analyses have been described in protocol CPMP.
Any borrowing of placebo or treatment effect informat ion will be specified in the ISA SAP.
Secondary  and Tertiary /Expl oratory  endpoints and analyses are described in protocol CPMP and 
DSA CPMP(1). 
9.4.2. Other Analyses 
9.4.2.1. Immunogenicity
Treatment -emergent ADAs are defined as participants
with a 2-fold (1 dilution) increase in t iter than the minimum requ ired dilut ion if no ADAs 
were detected at baseline (treatment -induced ADA) or 
with a 4-fold (2 dilutions) increase in titer compared with baseline if ADAs were detected 
at baseline (treatment -boosted ADA).
The frequency and percentage of participants withpreexist ing ADA and who are TE -ADA 
positive (TE -ADA+) to LY3016859 will be tabulated.   
If neutralizing ant ibodies are assessed, the distributio n of titers and frequency  of neutralizing 
antibodies for the TE -ADA+ participant smay also be tabulated.
The relationship between the presence of ant ibodies and PK parameters ,PD response ,safet y or
efficacy  to LY3016859, may also be assessed. Additional details may be provi ded in the SAP.
9.4.2.2. Pharmacokinetic and Pharmacodynamic Analyses
Pharmacokinet ic and pharmaco kinet ic-pharmacodynamic (PKPD) analyses maybe conducted to 
explore the exposure -response relat ionships for various pharmacodynamics measures. The
analys es will be perform edusing popul ation analysis software, NONMEM, if data all ows. The 
versio n of any  software used for the analysis will be documented, and the program will meet the 
Lilly requirements of software validat ion. It is possible that other validated, equivalent PK 
software programs may be used if appropriate, warranted, and approved by Glo bal P KPD
management .  Data may be pool ed withdata fro m other studi es for an integrated PKPD analysis.
The o bserved serum  concentrati ons for LY3016859 and epiregulin will be reported graphically 
and descript ively.
A limited number of pre -identified individuals independent of the study  team  may receive access
to unblinded data, as specified in the unblinding plan, prior to the interim or final database lock,
in order to init iate the final populat ion PK PDmodel devel opment processes. Informat ion that 
may unblind the study  during the analyses will not be reported to study  sites or blinded study  
team  until the study  has been unblinded.
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
329.5. Interim Analyses 
An interim analysis may be conducted for internal decisio n making. Unblinding details would 
be specified in the unblinding plan sect ion of the SAP or in a separate unblinding document. The 
SAPwill describe any  interim analyses in greater detail should they  occur. 
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
3310. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Clinical Laboratory Tests
The m aster protocol CPMP describes tests that may be performed at addi tional t imes noted in the 
SoA for this ISA.  This table describes tests unique for ISA OA01.  
Chemistry Urin e Chemistries Other Tests
Cystatin-C Albumin Immunogenicity
Creatinine Epiregulin
Albumin/creatinine 
ratio (ACR)LY3016859 
concentration
. Protein Urine pregnancy
Protein/creatinine 
ratio (PCR)
Refer to Section 10.3, Appendix 3for recommended l aboratory  testing for hy persensi tivity 
events.
CCI
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
3410.2. Appendix 2: Definitions of Reproductive Requirements and 
Contracepti onGuidance 
Women
Women of child- bearing potenti al may part icipate in this study.
Women of child- bearing potenti al must test negative for pregnancy  prior to ini tiation of 
treatm ent as indicated by  a negative serum pregnancy test at the screening visit fo llowed by  a 
negat ive urine pregnancy test within 24 hours prior to exposure.
Women of child- bearing potenti al who are completely  abstinent or in a same sex relat ionship ,as 
part of their preferred and usual lifest yle,must agree to either remain abst inent or stay  in a same 
sex rel ationship wit hout sexual relat ionships with males.
All ot herwom en of child- bearing potential must agree to use two forms of effective 
contraception, where at least one form is highly effective (less than 1% failure rate), for the 
entirety of the study . 
Abstinence or contraception must continue for 90 days after the l ast dose of intervent ion.
Acceptable Methods of Contraception
Highly effect ive method sof contracepti on (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives
implanted con tracepti ves,or 
intrauterine de vices . 
Effect ivemethod sof contraception comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges .  
Not Acceptable Methods of Contraception
Use of m ale and female condoms as a double barrier method is not considered acceptable due to 
the high failure rate when these barrier methods are combined .
Barri er protecti on m ethods wi thout concomi tant use of a spermicide are not a n effect ive or 
acceptable method of contracepti on. 
Periodic abst inence (e.g., calendar, ovulat ion, symptotherma l, post -ovulation methods), 
declaration of abst inence just for the duration of a trial, and withdrawal are not acceptable 
methods of contraception.
Women not of childbearing potential may participate and include those who 
have a congenital ano maly such as Mullerian agenesis 
areinfert ile due to surgical sterilizat ion, or 
are post- menopausal.  
Surgical sterilizat ion examples include
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
35hysterectomy 
bilateral  oophorectomy , or
tubal  ligation.  
At least 6 weeks must have passed after surgical bilateral oophorectomy wit h or without 
hysterectomy, or after tubal ligat ion.
Post-menopausal isdefined as either
a wom an at least 40 y ears of age with an intact uterus, not on hormone therapy , who has 
cessat ion of menses for at leas t 1 year wi thout an alternat ive medical cause, AND a 
follicle -stimulat ing horm one >40 m IU/mL
a wom an55 or ol der not on horm one therapy , who has had at l east 12 m onths of 
spontaneous amenorrhea, or
a wom anat least 55 y ears of age with a diagnosis of menop ause pri or to starting horm one 
replacement therapy .
Men
Men, regardl ess of their fertilit y status, m ust agree to ei ther remain abstinent (if this is their 
preferred and usual lifest yle) or use condoms as well as one addit ional highly effect ive method 
of contraception (less than 1% failure rate) or effective method of contraception with non-
pregnant women of child bearing potential partners for the duration of the study and until their 
plasma concentrations are below the level that could result in a relevant potenti al exposure to a 
possible fetus, predicted to be 6 months after the last dose.
Men wi th pregnant partners should use condoms during intercourse for the duration of the study  
and until the end of est imated relevant potential exposure to the fetus , predicted to be 6 months 
after the l ast dose.
Acceptable Methods of Contraception
Highly effect ive method sof contracepti on (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives
implanted con tracepti ves,or 
intrauterine devices .
Effectivemethod sof contraception comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges .  
Men and their partners may choose to use a double –barrier m ethod of contraception thatmust 
include use of a spermic ide.
Other Guidance
Men should refrain fro m sperm  donat ion for the durati on of  the study  and unt il their plasma 
concentrations are below the level that could result  in a relevant potenti al exposure to a possible 
fetus , 
predicted to be 6 months after the la st dose.
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
36Men who are in exclusively same sex relat ionships ,astheir pref erred and usual lifest yle,are not 
requi red to use contraception. 
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
3710.3. Appendix 3: Recommended Laboratory Testing for Hypersensitivity 
Events and Infusion -related Reactions
Reco mmended laboratory  tests should be perform ed at the tim e of a systemic hypersensit ivity 
event.  The management of the adverse event may  warrant l aboratory  testi ng bey ond that 
described below and should be performed as clinically indicated.
Laboratory  testing duri ng a Systemic Hypersensit ivity Event is performed to
help characterize and classify systemic hypersensitivit y react ions
meet regulatory  expectati ons, and
improve subsequent clinical management by  helping to di stinguish between the various 
mechanist ic bases of anaphylaxis .
If anaphyla xis is suspected or generalized urticaria is present, then
1.obtain a sample within 1 to2 hours of the event . 
a.samples may  be obtained as late as 12 hours after the event as analy tes can remain 
altered for an extended period of time
2. record the time at which the sample was collected , and
3. o btain a fo llow up sam ple at the next regularly  schedul ed visi t or af ter 4 weeks, 
whichever i s later.
Laboratory Tests for Hypersensitivity Events
Test Details
Tryptase If a try ptase sample is o btained more than 2 hours after the 
event (i.e. within 2 to 12 hours),or is not obtained because 
more than 12 hours have lapsed since the event, then obtain 
urine for N-methy lhistamine (NMH) testing. 
For tryptase serum samples obtained within 2 to 12 hour s 
of the event, urine NMH testing is performed in addition to 
tryptase testing. 
Collect the first void urine following the event. Obtain a 
follow up urine for NMH testing at the next regularly 
scheduled visit or after 4 weeks, whichever is later.
Anti-drug antibody (ADA) ADA testing should include drug specific IgE or the 
basophil activation test (BAT) .  The BAT requires a serum 
sample
LY3016859 pharmacokinetic concentration
Complement C3a, C5a
Cytokines IL-6, IL-1β, IL-10 (or any cytokine panel that includes 
these 3 cy tokines)
All tests will be performed by a Lilly- designated central  laboratory .
CONFIDENTIAL Master Protocol Number H0P -MC-CPMP ISA:H0P-MC-OA01 (a)
3811. References
CuiG, Wei R, Liu D, Yang H, Wu J, Fan L, Wang K. Associat ion of commo n variants in TGFA 
with increased risk of knee osteoarthrit is suscept ibilit y. Genet Test Molecular Biomarkers.
2017;21(10):586 -591.
Juhasz E, Kim JH, Klingelschmitt G, Walzer S. Effects of erlotinib first -line maintenance 
therapy  versus placebo on the healt h-related quali ty of life of pat ients with metastati c non -
small -cell l ung cancer. Eur J Cancer . 2013;49(6):1205 -1215.
Kersten C, Cameron MG. Cetuximab alleviates neuropathic pain despite t umour progressi on. 
BMJ Case Rep . 2012;2012. 
Kersten C, Cameron MG, Mjaland S. Epithelial growth factor receptor (EGFR) -inhibit ion for 
relief o f neuropathi c pain -A case series. Scand J Pain . 2013;4(1):3 -7.
Kersten C, Cameron MG, Laird B, Mjaland S. Epidermal growth factor receptor -inhibit ion 
(EGFR -I) in the treatment of neuropathic pain. Br J Anaesth . 2015;115(5):761 -767.
Martin LJ, Smit h SB, Khoutorsky  A, Magnussen CA, Samoshkin A, Sorge RE, Cho C, 
Yosefpou r N, Sivaselvachandran S, Tohy ama S, Col e T, Khuong TM, Mir E, Gibson DG, 
Wieskopf JS, Sotocinal SG, Aust in JS, Meloto CB, Gitt JH, Gkogkas C, Sonenberg N, 
Greenspan JD, Fillingim RB, Ohrbach R, Slade GD, Knott C, Dubner R, Nackley AG, 
Ribeiro -da-Silva A, Neely GG, Maixner W, Zaykin DV, Mogil JS, Diatchenko L . Epi regulin 
and EGFR interact ions are invo lved in pain processing. J Clin Invest . 2017;127(9):3353- 3366.
Moryl N, Obbens EA, Ozigbo OH, Kris MG. Analgesic effect of gefit inib in the treatment of 
non-small cell lung cancer. JSupport Oncol . 2006; 4(3):111.
Leo Document ID = 2a996bab-4ae1-4474-9036-4956b4de1f39
Approver: 
Approval Date & Time: 27-Mar-2020 14:35:03 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 27-Mar-2020 20:23:11 GMT
Signature meaning: Approved
PPD
PPD